Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.51 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604468 | 0.83 | NPC1 (0.51) | RAB9ANPC1MITFPKMSMN1; SMN2 | |
| SCHEMBL12604465 | 0.77 | NPC1 (0.55) | RAB9ANPC1MITFPKMMMP2 | |
| SCHEMBL8117377 | 0.77 | NPC1 (0.61) | RAB9ANPC1MITFPKMSMN1; SMN2 | |
| SCHEMBL8126626 | 0.76 | NPC1 (0.63) | RAB9ANPC1MITFPKMMMP2 | |
| SCHEMBL8117033 | 0.74 | NPC1 (0.69) | RAB9ANPC1MITFPKMSMN1; SMN2 | |
| SCHEMBL5454302 | 0.74 | NPC1 (0.77) | RAB9ANPC1MITFPKMSMN1; SMN2 | |
| SCHEMBL6956761 | 0.74 | NPC1 (0.62) | RAB9ANPC1MITFPKMSMN1; SMN2 | |
| SCHEMBL5384920 | 0.72 | NPC1 (0.79) | RAB9ANPC1MITFPKMSMN1; SMN2 | |
| SCHEMBL1690682 | 0.72 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL8127396 | 0.72 | NPC1 (0.65) | RAB9ANPC1MITFPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | RAB9A 2002/4885NPC1 1943/4885MITF 423/4885 |
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | RAB9A 2002/4885NPC1 1943/4885MITF 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.